Iterum Therapeutics plc (ITRMF) Amortization of Deferred Charges (2018 - 2025)

Iterum Therapeutics' Amortization of Deferred Charges history runs 8 years deep, the most recent figure standing at $194000.0 for Q1 2025.

• In Q1 2025, Amortization of Deferred Charges fell 65.91% year-over-year to $194000.0; the TTM figure through Sep 2025 stood at $769000.0 (down 66.55% YoY), while the FY2024 annual figure was $2.3 million, down 2.18% from the prior year.
• Amortization of Deferred Charges for Q1 2025 stood at $194000.0, down from $575000.0 in the prior quarter.
• The five-year high for Amortization of Deferred Charges was $2.4 million in Q1 2021, with the low at $28000.0 in Q3 2021.
• The 5-year median for Amortization of Deferred Charges is $575000.0 (2024), against an average of $592312.5.
• The sharpest annual moves came in 2021 and 2022: Amortization of Deferred Charges tumbled 98.64% in 2021, then soared 2010.71% in 2022.
• Iterum Therapeutics' Amortization of Deferred Charges stood at $461000.0 in 2021, then grew by 27.98% to $590000.0 in 2022, then fell by 0.68% to $586000.0 in 2023, then declined by 1.88% to $575000.0 in 2024, then tumbled by 66.26% to $194000.0 in 2025.
• Business Quant data shows ITRMF's Amortization of Deferred Charges at $194000.0 in Q1 2025, $575000.0 in Q4 2024, and $575000.0 in Q3 2024.